MIME-Version: 1.0
Content-Type: multipart/related; boundary="----=_NextPart_01D65958.8AD6B7D0"

Данный документ является веб-страницей в одном файле, также называемой файлом веб-архива. Если вы видите это сообщение, значит, данный браузер или редактор не поддерживает файлы веб-архива. Загрузите браузер, поддерживающий веб-архивы, например Windows® Internet Explorer®.

------=_NextPart_01D65958.8AD6B7D0
Content-Location: file:///C:/680AE759/UA42710101_4899.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="windows-1251"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml"
xmlns:st1=3D"urn:schemas-microsoft-com:office:smarttags"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dwindows-125=
1">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 14">
<meta name=3DOriginator content=3D"Microsoft Word 14">
<link rel=3DFile-List href=3D"UA42710101_4899.files/filelist.xml">
<link rel=3DPreview href=3D"UA42710101_4899.files/preview.wmf">
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"metricconverter"/>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>Valentyna Nedria</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>Bravada</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>1</o:TotalTime>
  <o:Created>2020-07-13T17:59:00Z</o:Created>
  <o:LastSaved>2020-07-13T17:59:00Z</o:LastSaved>
  <o:Pages>4</o:Pages>
  <o:Words>1805</o:Words>
  <o:Characters>10295</o:Characters>
  <o:Company>Teva</o:Company>
  <o:Lines>85</o:Lines>
  <o:Paragraphs>24</o:Paragraphs>
  <o:CharactersWithSpaces>12076</o:CharactersWithSpaces>
  <o:Version>14.00</o:Version>
 </o:DocumentProperties>
 <o:OfficeDocumentSettings>
  <o:RelyOnVML/>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]-->
<link rel=3DthemeData href=3D"UA42710101_4899.files/themedata.thmx">
<link rel=3DcolorSchemeMapping href=3D"UA42710101_4899.files/colorschememap=
ping.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:HyphenationZone>21</w:HyphenationZone>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>RU</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:DontUseIndentAsNumberingTabStop/>
   <w:FELineBreak11/>
   <w:WW11IndentRules/>
   <w:DontAutofitConstrainedTables/>
   <w:AutofitLikeWW11/>
   <w:HangulWidthLikeWW11/>
   <w:UseNormalStyleForList/>
   <w:DontVertAlignCellWithSp/>
   <w:DontBreakConstrainedForcedTables/>
   <w:DontVertAlignInTxbx/>
   <w:Word11KerningPairs/>
   <w:CachedColBalance/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val=3D"Cambria Math"/>
   <m:brkBin m:val=3D"before"/>
   <m:brkBinSub m:val=3D"&#45;-"/>
   <m:smallFrac m:val=3D"off"/>
   <m:dispDef/>
   <m:lMargin m:val=3D"0"/>
   <m:rMargin m:val=3D"0"/>
   <m:defJc m:val=3D"centerGroup"/>
   <m:wrapIndent m:val=3D"1440"/>
   <m:intLim m:val=3D"subSup"/>
   <m:naryLim m:val=3D"undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState=3D"false" DefUnhideWhenUsed=3D"true"
  DefSemiHidden=3D"true" DefQFormat=3D"false" DefPriority=3D"99"
  LatentStyleCount=3D"267">
  <w:LsdException Locked=3D"false" Priority=3D"0" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Normal"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"heading 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 7"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 8"/>
  <w:LsdException Locked=3D"false" Priority=3D"9" QFormat=3D"true" Name=3D"=
heading 9"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 7"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 8"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" Name=3D"toc 9"/>
  <w:LsdException Locked=3D"false" Priority=3D"35" QFormat=3D"true" Name=3D=
"caption"/>
  <w:LsdException Locked=3D"false" Priority=3D"10" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Title"/>
  <w:LsdException Locked=3D"false" Priority=3D"1" Name=3D"Default Paragraph=
 Font"/>
  <w:LsdException Locked=3D"false" Priority=3D"11" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtitle"/>
  <w:LsdException Locked=3D"false" Priority=3D"22" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Strong"/>
  <w:LsdException Locked=3D"false" Priority=3D"20" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"59" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" Name=3D"Table Grid"/>
  <w:LsdException Locked=3D"false" UnhideWhenUsed=3D"false" Name=3D"Placeho=
lder Text"/>
  <w:LsdException Locked=3D"false" Priority=3D"1" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"No Spacing"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" UnhideWhenUsed=3D"false" Name=3D"Revisio=
n"/>
  <w:LsdException Locked=3D"false" Priority=3D"34" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"List Paragraph"/>
  <w:LsdException Locked=3D"false" Priority=3D"29" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Quote"/>
  <w:LsdException Locked=3D"false" Priority=3D"30" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Quote"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 1"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 2"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 3"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 4"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 5"/>
  <w:LsdException Locked=3D"false" Priority=3D"60" Name=3D"Light Shading Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"61" Name=3D"Light List Accen=
t 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"62" Name=3D"Light Grid Accen=
t 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"63" Name=3D"Medium Shading 1=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"64" Name=3D"Medium Shading 2=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"65" Name=3D"Medium List 1 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"66" Name=3D"Medium List 2 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"67" Name=3D"Medium Grid 1 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"68" Name=3D"Medium Grid 2 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"69" Name=3D"Medium Grid 3 Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"70" Name=3D"Dark List Accent=
 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"71" Name=3D"Colorful Shading=
 Accent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"72" Name=3D"Colorful List Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"73" Name=3D"Colorful Grid Ac=
cent 6"/>
  <w:LsdException Locked=3D"false" Priority=3D"19" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtle Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"21" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Emphasis"/>
  <w:LsdException Locked=3D"false" Priority=3D"31" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Subtle Reference"/>
  <w:LsdException Locked=3D"false" Priority=3D"32" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Intense Reference"/>
  <w:LsdException Locked=3D"false" Priority=3D"33" SemiHidden=3D"false"
   UnhideWhenUsed=3D"false" QFormat=3D"true" Name=3D"Book Title"/>
  <w:LsdException Locked=3D"false" Priority=3D"37" Name=3D"Bibliography"/>
  <w:LsdException Locked=3D"false" Priority=3D"39" QFormat=3D"true" Name=3D=
"TOC Heading"/>
 </w:LatentStyles>
</xml><![endif]--><!--[if !mso]><object
 classid=3D"clsid:38481807-CA0E-42D2-BF39-B33AF135CC4D" id=3Dieooui></objec=
t>
<style>
st1\:*{behavior:url(#ieooui) }
</style>
<![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;
	mso-font-charset:204;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520092929 1073786111 9 0 415 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:204;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520081665 -1073717157 41 0 66047 0;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;
	mso-font-charset:204;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520084737 -1073683329 41 0 479 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:10.0pt;
	margin-left:0cm;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:EN-US;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-priority:99;
	mso-style-link:"Верхний колонтитул Знак";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 242.2pt right 484.45pt;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:EN-US;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-priority:99;
	mso-style-link:"Нижний колонтитул Знак";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 242.2pt right 484.45pt;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:EN-US;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Текст выноски Знак";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:9.0pt;
	font-family:"Segoe UI","sans-serif";
	mso-fareast-font-family:Calibri;
	mso-fareast-language:EN-US;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{mso-style-priority:1;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin:0cm;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:UK;
	mso-fareast-language:EN-US;}
span.a
	{mso-style-name:"Верхний колонтитул Знак";
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Верхний колонтитул";}
span.a0
	{mso-style-name:"Нижний колонтитул Знак";
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Нижний колонтитул";}
span.a1
	{mso-style-name:"Текст выноски Знак";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Текст выноски";
	mso-ansi-font-size:9.0pt;
	mso-bidi-font-size:9.0pt;
	font-family:"Segoe UI","sans-serif";
	mso-ascii-font-family:"Segoe UI";
	mso-hansi-font-family:"Segoe UI";
	mso-bidi-font-family:"Segoe UI";}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	mso-ascii-font-family:Calibri;
	mso-fareast-font-family:Calibri;
	mso-hansi-font-family:Calibri;}
 /* Page Definitions */
 @page
	{mso-footnote-separator:url("UA42710101_4899.files/header.htm") fs;
	mso-footnote-continuation-separator:url("UA42710101_4899.files/header.htm"=
) fcs;
	mso-endnote-separator:url("UA42710101_4899.files/header.htm") es;
	mso-endnote-continuation-separator:url("UA42710101_4899.files/header.htm")=
 ecs;}
@page WordSection1
	{size:595.3pt 841.9pt;
	margin:35.45pt 42.5pt 42.55pt 63.8pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:6.9pt;
	mso-footer:url("UA42710101_4899.files/header.htm") f1;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 @list l0
	{mso-list-id:493499007;
	mso-list-type:hybrid;
	mso-list-template-ids:-858498842 68747265 68747267 68747269 68747265 68747=
267 68747269 68747265 68747267 68747269;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:36.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;
	font-family:Symbol;}
@list l0:level2
	{mso-level-tab-stop:72.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level3
	{mso-level-tab-stop:108.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level4
	{mso-level-tab-stop:144.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level5
	{mso-level-tab-stop:180.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level6
	{mso-level-tab-stop:216.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level7
	{mso-level-tab-stop:252.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level8
	{mso-level-tab-stop:288.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level9
	{mso-level-tab-stop:324.0pt;
	mso-level-number-position:left;
	text-indent:-18.0pt;}
@list l0:level1 lfo1
	{mso-level-start-at:0;}
ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Обычная таблица";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Calibri","sans-serif";
	mso-bidi-font-family:"Times New Roman";}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext=3D"edit" spidmax=3D"1026"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext=3D"edit">
  <o:idmap v:ext=3D"edit" data=3D"1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=3DRU style=3D'tab-interval:35.4pt'>

<div class=3DWordSection1>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:13.7pt;mso-line-height-rule:exactly;mso-pagin=
ation:
none;tab-stops:lined 461.5pt;background:white;mso-layout-grid-align:none;
text-autospace:none'><b><span lang=3DUK style=3D'font-size:12.0pt;font-fami=
ly:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";letter-spacing:2.65pt;mso-ansi-la=
nguage:
UK;mso-fareast-language:RU'>ІНСТРУКЦІЯ</span></b><span lang=3DUK
style=3D'font-size:10.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'><o:p></o:p>=
</span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-top:0cm;margin-right:-3=
.25pt;
margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:center;
line-height:13.7pt;mso-line-height-rule:exactly;mso-pagination:none;backgro=
und:
white;mso-layout-grid-align:none;text-autospace:none'><b><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";letter-spacing:-.1pt;mso-ansi-language:UK;mso-fareast-lan=
guage:
RU'>для медичного застосування лікарського засобу<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:115.2pt;margin-bo=
ttom:
0cm;margin-left:214.55pt;margin-bottom:.0001pt;text-align:justify;text-inde=
nt:
-76.8pt;line-height:13.7pt;mso-line-height-rule:exactly;mso-pagination:none;
background:white;mso-layout-grid-align:none;text-autospace:none'><b><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal;mso-pagination:none;mso-layout-grid-al=
ign:
none;text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><span la=
ng=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Тевалор-Тев=
а<o:p></o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal;mso-pagination:none;mso-layout-grid-al=
ign:
none;text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><span la=
ng=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>(</span></b=
><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DEN-US style=3D'font-size=
:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:EN-US;mso-fareast-language:RU'>Tevalor</span></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DUK style=3D'font-size:12=
.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:RU'>-</span></b><b style=3D'mso-b=
idi-font-weight:
normal'><span lang=3DEN-US style=3D'font-size:12.0pt;font-family:"Times New=
 Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-US;mso-farea=
st-language:
RU'>Teva</span></b><b style=3D'mso-bidi-font-weight:normal'><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>)<o:p></o:p=
></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal;mso-pagination:none;mso-layout-grid-al=
ign:
none;text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><span la=
ng=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;=
</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b><i><span lang=3DUK style=3D'font-size:12.0pt;font-f=
amily:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";mso-ans=
i-language:
UK;mso-fareast-language:RU'>Склад:<o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;text-autospace:ideograph-numeric'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:UK'>діючі речовини: </span></i><s=
pan
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>1 таблетка містить деквалінію хлориду 0,25 мг; кислоти аскорбінової 30 =
мг;<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;text-autospace:ideograph-numeric'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:UK'>допоміжні речовини: </span></=
i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>глюкози моногідрат, сахарин натрію, пектин, ванілін, сахароза, какао
порошок, лактози моногідрат, магнію стеарат. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:6.0pt;line-height:normal;mso-pa=
gination:
none;mso-layout-grid-align:none;text-autospace:none'><b><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Лікарська
форма.</span></b><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Tim=
es New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'> </span><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times Ne=
w Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>Таблетки для смоктання.<b style=3D'mso-bidi-font-weight:normal'><o:p></=
o:p></b></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;text-autospace:ideograph-numeric'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:RU'>Основні фізико-хімічні власти=
вості:</span></i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'> круглі плоскі таблетки з двосторонньою фаскою та насічкою з однієї сто=
рони,
діаметром 13 мм; колір коричневий, мозаїчний</span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-bidi-font-family:Tahoma;mso-ansi-language:UK;mso-fare=
ast-language:
UK'>.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal;mso-pagination:none;mso-layout-grid-align:none;text-autospace:none'>=
<b><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Фармакотерапевтична група. <o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal;mso-pagination:none;mso-layout-grid-align:none;text-autospace:none'>=
<span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>Препарати, що застосовуються при захворюваннях горла.<i> </i><span
style=3D'mso-bidi-font-weight:bold'>Різні антисептики.</span><o:p></o:p></s=
pan></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;text-autospace:ideograph-numeric'><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>Код АТХ </s=
pan><span
lang=3DEN-US style=3D'font-size:12.0pt;font-family:"Times New Roman","serif=
";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-US;mso-farea=
st-language:
UK'>R</span><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times Ne=
w Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>02А А20.</span><span style=3D'font-size:12.0pt;font-family:"Times New R=
oman","serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><span lang=3D=
UK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;=
</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:RU'>Фармакологічні властивості.<o=
:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Фармакодина=
міка.
<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Тевалор-Тева – комбінований лікарський засіб з добре вираженою місцевою
антисептичною, антибактеріальною і протигрибковою дією. Застосовується при
запаленнях горла. Проявляє в основному бактеріостатичну (за деякими даними –
бактерицидну) дію відносно ряду грампозитивних та грамнегативних
мікроорганізмів, у тому числі штамів, стійких до антибіотиків. Препарат
найефективніший при лужному значенні рН (як середовище у порожнині рота). Д=
еквалінію
хлорид є місцевим антисептиком групи квінолінів. Він являє собою
біс-четвертинний квінолін з антисептичною і бактеріостатичною дією.<o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Деквалінію хлорид має антисептичну дію, переважно місцеву; антибактеріа=
льну
дію – головним чином відносно грамнегативних та грампозитивних мікроорганіз=
мів,
переважно відносно гноєтворних збудників та штамів, стійких до антибіотиків
(піогенні стрептококи, <i style=3D'mso-bidi-font-style:normal'>Borrelia</i>
тощо); протигрибкову дію – головним чином проти <i style=3D'mso-bidi-font-s=
tyle:
normal'>Candida albicans</i>, деяких видів <i style=3D'mso-bidi-font-style:=
normal'>Tr</i></span><i
style=3D'mso-bidi-font-style:normal'><span lang=3DEN-US style=3D'font-size:=
12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:EN-US;mso-fareast-language:RU'>i</span></i><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:RU'>chophyton</span></i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'> та епідермофітів. Не проявляє активності проти <i style=3D'mso-bidi-fo=
nt-style:
normal'>Mycobacterium.</i> Антибактеріальна дія зумовлена денатурацією білк=
ів і
ферментів збудників шляхом розчинення і деполімеризації, а також гліколізом=
 і інактивацією
дегідрогеназ – спочатку дія оборотна, однак довготривалий контакт зі збудни=
ком
інактивує їх необоротно; порушенням синтезу білків на рівні рибосом; цитолі=
зом
клітинної мембрани. Поверхнево-активна катіонна дія лежить в основі
бактеріостатичної активності, вона сильніша відносно грампозитивних, ніж ві=
дносно
грамнегативних мікроорганізмів.</span><span style=3D'font-size:12.0pt;font-=
family:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";mso-far=
east-language:
RU'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Аскорбінова кислота, що входить до складу препарату, діє на
внутрішньоклітинні процеси окислення та відновлення; збільшує синтез
специфічних антибактеріальних антитоксинів та покращує функції
ретикулоендотелію; зменшує проникність клітинних мембран; покращує стан кап=
ілярів
судинної стінки та обмежує ексудативні, запальні та алергічні реакції.<o:p>=
</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Стійкість мікроорганізмів до лікарського засобу Тевалор-Тева розвиваєть=
ся
повільно, при довготривалому прийомі (понад 15–20 діб). Розвиток стійкості
мінімальний для грампозитивних мікроорганізмів та деяких грибів, лікарський
засіб ефективний відносно мікроорганізмів, стійких до пеніциліну, стрептомі=
цину
і сульфонаміду.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Фармакокіне=
тика.
<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Проявляє місцеву антисептичну дію у ротовій порожнині. Абсорбується шви=
дко
зі шлунково-кишкового тракту. Розподіляється за допомогою дифузії через
печінку, легені, нирки. Виведення тривале з сечею та калом. <o:p></o:p></sp=
an></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b><span lang=3DUK style=3D'font-size:12.0pt;font-fami=
ly:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Клінічні характеристики.<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b><i><span lang=3DUK style=3D'font-size:12.0pt;font-f=
amily:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";mso-ans=
i-language:
UK;mso-fareast-language:RU'>Показання.<o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21=
.3pt;
line-height:normal;mso-list:l0 level1 lfo1;tab-stops:list 21.3pt 36.0pt;
text-autospace:ideograph-numeric'><![if !supportLists]><span lang=3DUK
style=3D'font-size:12.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol;mso-ansi-language:UK;mso-fareast-language:UK;
mso-bidi-font-weight:bold'><span style=3D'mso-list:Ignore'>·<span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:UK;mso-bidi-font-weight:bold'>Міс=
цеве
антисептичне лікування запальних процесів ротової порожнини і горла,
спричинених чутливими до препарату збудниками (катаральні, виразкові, фібро=
зні
гінгівіти, афтозні стоматити, кандидоз, фарингіти, тонзиліти, ларингіти і
глосити).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21=
.3pt;
line-height:normal;mso-list:l0 level1 lfo1;tab-stops:list 21.3pt 36.0pt;
text-autospace:ideograph-numeric'><![if !supportLists]><span lang=3DUK
style=3D'font-size:12.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol;mso-ansi-language:UK;mso-fareast-language:UK;
mso-bidi-font-weight:bold'><span style=3D'mso-list:Ignore'>·<span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:UK'>У комплексному лікуванні більш
тяжких інфекцій горла у поєднанні з антибіотиками та сульфонамідами.<span
style=3D'mso-bidi-font-weight:bold'><o:p></o:p></span></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:21.3pt;margin-bottom:.0001pt;text-align:justify;text-indent:-21=
.3pt;
line-height:normal;mso-list:l0 level1 lfo1;tab-stops:list 21.3pt 36.0pt;
text-autospace:ideograph-numeric'><![if !supportLists]><span lang=3DUK
style=3D'font-size:12.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
mso-bidi-font-family:Symbol;mso-ansi-language:UK;mso-fareast-language:UK;
mso-bidi-font-weight:bold'><span style=3D'mso-list:Ignore'>·<span
style=3D'font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;=
&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:UK;mso-bidi-font-weight:bold'>Про=
філактика
інфекцій до та після оперативних втручань у порожнині рота і горла.<o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:7.45pt;margin-bot=
tom:
0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:no=
rmal;
mso-pagination:none;background:white;mso-layout-grid-align:none;text-autosp=
ace:
none'><b><i><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times Ne=
w Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Протипоказання. </span></i></b><i><span lang=3DUK style=3D'font-size:12=
.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:RU'><span
style=3D'mso-spacerun:yes'> </span><o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Гіперчутливість до діючих речовин або до будь-якої з допоміжних речовин.
Тромбоз, схильність до тромбозів, тромбофлебіти, тяжкі захворювання нирок,
цукровий діабет, непереносимість фруктози, дефіцит лактази Лаппа або синдром
мальабсорбції глюкози-галактози. Алергія до четвертинних амонієвих сполук
(наприклад бензалконію хлориду).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:.5pt;margin-bottom:.0001pt;text-align:justify;line-height:norma=
l;
mso-pagination:none;background:white;mso-layout-grid-align:none;text-autosp=
ace:
none'><b><i><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times Ne=
w Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Взаємодія з іншими лікарськими засобами та інші види взаємодій. <o:p></=
o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:.5pt;margin-bottom:.0001pt;text-align:justify;line-height:norma=
l;
mso-pagination:none;background:white;mso-layout-grid-align:none;text-autosp=
ace:
none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roma=
n","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU;mso-bidi-font-weight:bold;mso-bidi-font-style:italic'>Антибактеріальна а=
ктивність
деквалінію хлориду знижується при одночасному застосуванні детергентів,
наприклад зубної пасти.</span><span lang=3DUK> </span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU;mso-bidi-fon=
t-weight:
bold;mso-bidi-font-style:italic'>Застосування лікарського засобу не слід
поєднувати з прийомом інгібіторів холінестерази.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>Абсорбція аскорбінової кислоти знижується при одночасному застосуванні
пероральних контрацептивних засобів, вживанні фруктових або овочевих соків,
лужного пиття. Аскорбінова кислота при пероральному застосуванні підвищує
абсорбцію пеніциліну, тетрацикліну, заліза, а також сприяє всмоктуванню
алюмінію в кишечнику, що слід врахувати при одночасному лікуванні антацидам=
и,
що містять алюміній.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>Аскорбінова кислота знижує ефективність гепарину та непрямих
антикоагулянтів, підвищує ризик розвитку кристалурії при лікуванні
саліцилатами. Одночасний прийом аскорбінової кислоти і дефероксаміну підвищ=
ує
тканинну токсичність заліза, особливо у серцевому м’язі, що може призвести =
до
декомпенсації системи кровообігу. Аскорбінову кислоту можна приймати лише ч=
ерез
2 години після ін’єкції дефероксаміну. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>Тривалий прийом великих доз аскорбінової кислоти особами, які лікуються
дисульфіраміном, гальмує дисульфірам-алкогольну реакцію. Великі дози
аскорбінової кислоти зменшують ефективність трициклічних антидепресантів,
нейролептиків – похідних фенотіазину, канальцеву реабсорбцію амфетаміну,
порушують виведення мексилетину нирками.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>Аскорбінова кислота підвищує загальний кліренс етилового спирту. Препар=
ати
хінолінового ряду, кальцію хлорид, саліцилати, кортикостероїди при тривалому
застосуванні зменшують запаси аскорбінової кислоти в організмі.<o:p></o:p><=
/span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>При одночасному прийомі з полістиролсульфонатом (кайєксалатом), засобом=
 для
лікування гіперкаліємії, є вірогідність розвитку тяжких некротичних уражень
шкіри і слизових оболонок, особливо – шлунково-кишкового тракту.<o:p></o:p>=
</span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;background:white;mso-layout-=
grid-align:
none;text-autospace:none'><b><i><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:RU'>Особливості застосування.<o:p=
></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>У зв’язку з відсутністю у лікарському засобі знеболювального компонента
його недоцільно застосовувати при запальних процесах, що супроводжуються
сильним болем у горлі. При наявності основних клінічних симптомів генераліз=
ації
інфекції необхідно звернутися до лікаря, який призначить системне
антибактеріальне лікування. При появі будь-яких побічних ефектів прийом Тев=
алору-Тева
треба припинити. Одночасний прийом з іншими препаратами для місцевого лікув=
ання
слід проводити обережно, під контролем лікаря. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>Всмоктування аскорбінової кислоти може порушуватися при кишкових
дискінезіях, ентеритах та ахілії. З обережністю застосовувати для лікування
пацієнтів з дефіцитом <br>
глюкозо-6-фосфатдегідрогенази.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>Аскорбінова кислота як відновник може впливати на результати лабораторн=
их
досліджень, наприклад, при визначенні вмісту в крові глюкози, білірубіну,
активності трансаміназ, лактатдегідрогенази.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>При прийомі аскорбінової кислоти понад <st1:metricconverter ProductID=
=3D"1 г"
w:st=3D"on">1 г</st1:metricconverter> на добу і тривалому застосуванні, що
перевищує більш ніж в три рази рекомендовану добову дозу та тривалість
лікування препаратом <br>
Тевалор-Тева, необхідно контролювати функцію нирок та рівень артеріального
тиску, а також функцію підшлункової залози. Слід з обережністю застосовуват=
и лікарський
засіб пацієнтам із захворюванням нирок в анамнезі та</span><span lang=3DUK
style=3D'mso-ansi-language:UK'> </span><span lang=3DUK style=3D'font-size:1=
2.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:UK'>пацієнтам з прогресуючим
онкологічним захворюванням, оскільки може ускладнитися перебіг хвороби. <o:=
p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>При сечокам’яній хворобі добова доза аскорбінової кислоти не має
перевищувати 1 г, бо існує ризик утворення кальцій-оксалатних каменів при
застосуванні високих доз аскорбінової кислоти у хворих, схильних до утворен=
ня
каменів у нирках. Препарат хворим на галактоземію слід застосовувати з
обережністю. Оскільки аскорбінова кислота підвищує абсорбцію заліза, її
застосування у високих дозах, понад 1&nbsp;г, може бути небезпечним для
пацієнтів з гемохроматозом, таласемією, поліцитемією, лейкемією і
сидеробластною анемією. Пацієнтам з високим вмістом заліза в організмі слід
застосовувати препарат у рекомендованих дозах.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>Не слід призначати великі дози препарату хворим з підвищеним згортанням
крові. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>До складу лікарського засобу </span><span style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-fareast-language:UK'>вход</span><span lang=3DUK style=3D'font-size:12.0=
pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:UK'>я</span><span style=3D'font-s=
ize:
12.0pt;font-family:"Times New Roman","serif";mso-fareast-font-family:"Times=
 New Roman";
mso-fareast-language:UK'>ть</span><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:UK'> глюкоза, лактоза, сахароза.<=
/span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'> </span>=
<span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>Якщо у Вас встановлена непереносимість деяких цукрів, проконсультуйтеся=
 з
лікарем, перш ніж приймати цей лікарський засіб (див. розділ «Протипоказанн=
я»).</span><span
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-fareast-language:UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;background:white;mso-layout-=
grid-align:
none;text-autospace:none'><b><i><span style=3D'font-size:12.0pt;font-family=
:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'><o:p>&nb=
sp;</o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i><span lang=3DUK style=3D'font-size:12.0pt;font-fami=
ly:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU;mso-bidi-font-weight:bold'>Застосування у період вагітності або годування
груддю.<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>У період вагітності або годування груддю застосовувати з обережністю, п=
ід
контролем лікаря, суворо дотримуючись рекомендованих доз.<o:p></o:p></span>=
</p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i><span lang=3DUK style=3D'font-size:12.0pt;font-fami=
ly:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU;mso-bidi-font-weight:bold'><o:p>&nbsp;</o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i><span lang=3DUK style=3D'font-size:12.0pt;font-fami=
ly:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU;mso-bidi-font-weight:bold'>Здатність впливати на швидкість реакції при
керуванні автотранспортом або іншими механізмами.<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Лікарський засіб Тевалор-Тева не впливає на здатність пацієнта виконува=
ти
роботи, що потребують підвищеної уваги (керування автотранспортом і робота з
механізмами, що рухаються).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b><i><span lang=3DUK style=3D'font-size:12.0pt;font-f=
amily:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";mso-ans=
i-language:
UK;mso-fareast-language:RU'>Спосіб застосування та дози. <o:p></o:p></span>=
</i></b></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:-2.9pt;margin-bot=
tom:
0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:no=
rmal;
text-autospace:ideograph-numeric'><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:UK'>Дорослим та дітям віком від 4
років застосовувати по 1 таблетці для смоктання через <br>
кожні 2–3 години (не більше 8–10 таблеток за добу).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:-2.9pt;margin-bot=
tom:
0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:no=
rmal;
text-autospace:ideograph-numeric'><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:UK'>Таблетки не розжовувати. Післ=
я прийому
лікарського засобу пацієнтові рекомендується не їсти і не пити протягом 30
хвилин.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:-2.9pt;margin-bot=
tom:
0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:no=
rmal;
text-autospace:ideograph-numeric'><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:UK'>Лікування рекомендується
продовжувати ще протягом 1–2 діб після зникнення симптомів захворювання.
Загальна тривалість лікування не має перевищувати 5–7 діб (виникає небезпека
порушення розвитку нормальної бактеріальної флори у порожнині рота і в горл=
і).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;tab-stops:404.0pt;mso-layout=
-grid-align:
none;text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lan=
g=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Діти.<o:p><=
/o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:.5pt;margin-bottom:.0001pt;text-align:justify;line-height:norma=
l;
mso-pagination:none;background:white;mso-layout-grid-align:none;text-autosp=
ace:
none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roma=
n","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Лікарський засіб не застосовувати дітям віком до 4 років у даній лікарс=
ькій
формі через ризик розвитку аспірації.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:.5pt;margin-bottom:.0001pt;text-align:justify;line-height:norma=
l;
mso-pagination:none;background:white;mso-layout-grid-align:none;text-autosp=
ace:
none'><b><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New R=
oman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:.25pt;margin-bottom:.0001pt;text-align:justify;line-height:norm=
al;
mso-pagination:none;background:white;mso-layout-grid-align:none;text-autosp=
ace:
none'><b><i><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times Ne=
w Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Передозування. <o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;background:white;mso-layout-=
grid-align:
none;text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-fa=
mily:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";mso-ans=
i-language:
UK;mso-fareast-language:RU'>Посилення проявів побічних реакцій.<o:p></o:p><=
/span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Кислота аскорбінова добре переноситься. Вона є водорозчинним вітаміном,=
 її
надмірна кількість виводиться з сечею. Однак при тривалому застосуванні
вітаміну С у великих дозах можливе пригнічення функції інсулярного апарату
підшлункової залози, що вимагає контролю за станом останньої. Передозування
може призвести до змін ниркової екскреції аскорбінової та сечової кислот під
час ацетилування сечі з ризиком випадання в осад оксалатних конкрементів.<o=
:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;background:white;mso-layout-=
grid-align:
none;text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-fa=
mily:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";mso-ans=
i-language:
UK;mso-fareast-language:RU'>Застосування великих доз препарату може призвес=
ти
до блювання, нудоти або діареї, які зникають після його відміни, у рідкісних
випадках можуть виникати виразки та некроз стравоходу. Лікування симптомати=
чне.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;background:white;mso-layout-=
grid-align:
none;text-autospace:none'><b><i><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></i><=
/b></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:0cm;margin-bottom=
:0cm;
margin-left:.5pt;margin-bottom:.0001pt;text-align:justify;line-height:norma=
l;
mso-pagination:none;background:white;mso-layout-grid-align:none;text-autosp=
ace:
none'><b><i><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times Ne=
w Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Побічні реакції. <o:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:-2.9pt;margin-bot=
tom:
0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:no=
rmal;
mso-pagination:none;mso-layout-grid-align:none;text-autospace:none'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>Лікарський засіб зазвичай переноситься добре, не подразнює тканини у мі=
сці
застосування, повідомлень про серйозні побічні дії не було. Проте можливі т=
акі небажані
медикаментозні реакції, пов’язані з деквалінію хлоридом: <o:p></o:p></span>=
</p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:-2.9pt;margin-bot=
tom:
0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:no=
rmal;
mso-pagination:none;mso-layout-grid-align:none;text-autospace:none'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:UK'>з боку травного тракту:</span=
></i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'> нудота, блювання, відчуття печіння і подразнення у горлі, сухість у
порожнині рота, дисбактеріоз ротової порожнини (при тривалому застосуванні у
високих дозах);<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:-2.9pt;margin-bot=
tom:
0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:no=
rmal;
mso-pagination:none;mso-layout-grid-align:none;text-autospace:none'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:UK'>інше:</span></i><span lang=3D=
UK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'> дуже рідко=
 – алергічні
реакції;<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:-2.9pt;margin-bot=
tom:
0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:no=
rmal;
mso-pagination:none;mso-layout-grid-align:none;text-autospace:none'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:UK'>місцеві реакції:</span></i><s=
pan
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'> у рідкісних випадках, а саме при зловживанні – виникнення виразки та
некрозу.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-top:0cm;margin-right:-2.9pt;margin-bot=
tom:
0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:no=
rmal;
mso-pagination:none;mso-layout-grid-align:none;text-autospace:none'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>Можливі такі небажані реакції, пов’язані з аскорбіновою кислотою:<o:p><=
/o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>з боку імун=
ної
системи: </span></i><span lang=3DUK style=3D'font-size:12.0pt;font-family:"=
Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>алергічні реакції, включаючи висипання, свербіж, ангіоневротичний набря=
к, кропив’янку;
іноді – анафілактичний шок при наявності сенсибілізації;<o:p></o:p></span><=
/p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>з боку шкір=
и та
підшкірної клітковини:</span></i><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:UK'> екзема;<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>з боку
серцево-судинної системи:</span></i><span lang=3DUK style=3D'font-size:12.0=
pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:UK'> артеріальна гіпертензія;<o:p=
></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>з боку нерв=
ової
системи:</span></i><span lang=3DUK style=3D'font-size:12.0pt;font-family:"T=
imes New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'> підвищена збудливість, порушення сну, головний біль, відчуття жару,
стомлюваність;<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";mso-fareast=
-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>при тривало=
му
застосуванні у високих дозах (понад 1 г аскорбінової кислоти на добу):</spa=
n></i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'> ушкодження інсулярного апарату підшлункової залози (гіперглікемія,
глюкозурія) та порушення синтезу глікогену аж до появи цукрового діабету;
дистрофія міокарда; тромбоцитоз, гіперпротромбінемія, еритроцитопенія,
нейтрофільний лейкоцитоз; у хворих із недостатністю глюкозо-6-фосфатдегідро=
генази
в еритроцитах можливий гемоліз; дисбактеріоз ротової порожнини; подразнення
слизової оболонки шлунково-кишкового тракту, печія, блювання, діарея;
ушкодження гломерулярного апарату нирок, кристалурія, утворення уратних,
цистонових та/або оксалатних конкрементів у нирках та сечовивідних шляхах,
ниркова недостатність; порушення обміну цинку, міді.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b><i><span lang=3DUK style=3D'font-size:12.0pt;font-f=
amily:
"Times New Roman","serif";mso-fareast-font-family:"Times New Roman";mso-ans=
i-language:
UK;mso-fareast-language:RU'>Термін придатності</span></i></b><b
style=3D'mso-bidi-font-weight:normal'><i style=3D'mso-bidi-font-style:norma=
l'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>.</span></i></b><span lang=3DUK style=3D'font-size:12.0pt;font-family:"=
Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'> </span><span style=3D'font-size:12.0pt;font-family:"Times New Roman","=
serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>3 роки.<=
/span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b><span lang=3DUK style=3D'font-size:12.0pt;font-fami=
ly:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b><span lang=3DUK style=3D'font-size:12.0pt;font-fami=
ly:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Умови зберігання.</span></b><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:RU'> <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>Зберігати в оригінальній упаковці<b style=3D'mso-bidi-font-weight:norma=
l'> </b>при
температурі не вище 25 </span><span style=3D'font-size:12.0pt;font-family:"=
Times New Roman","serif"'>°</span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>С.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>Зберігати у місцях, недоступних для дітей!<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b><span lang=3DUK style=3D'font-size:12.0pt;font-fami=
ly:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Упаковка. </span></b><span style=3D'font-size:12.0pt;font-family:"Times=
 New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>По 20
таблеток у </span><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Ti=
mes New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>блістері, 1 або 2 блістери в картонній пачці.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b><span lang=3DUK style=3D'font-size:12.0pt;font-fami=
ly:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Категорія відпуску. </span></b><span lang=3DUK style=3D'font-size:12.0p=
t;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:RU;mso-bidi-font-weight:bold'>Без
рецепта.</span><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times=
 New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b><span lang=3DUK style=3D'font-size:12.0pt;font-fami=
ly:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'><o:p>&nbsp;</o:p></span></b></p>

<div style=3D'mso-element:frame;mso-element-frame-hspace:9.0pt;mso-element-=
wrap:
around;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
column;mso-height-rule:exactly'>

<table cellspacing=3D0 cellpadding=3D0 hspace=3D0 vspace=3D0 align=3Dleft>
 <tr>
  <td valign=3Dtop align=3Dleft style=3D'padding-top:0cm;padding-right:9.0p=
t;
  padding-bottom:0cm;padding-left:9.0pt'>
  <p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;lin=
e-height:
  normal;mso-pagination:none;mso-layout-grid-align:none;text-autospace:none;
  mso-element:frame;mso-element-frame-hspace:9.0pt;mso-element-wrap:around;
  mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:colum=
n;
  mso-height-rule:exactly'><b><span lang=3DUK style=3D'font-size:12.0pt;fon=
t-family:
  "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
  mso-ansi-language:UK;mso-fareast-language:RU'>Виробник. <o:p></o:p></span=
></b></p>
  </td>
 </tr>
</table>

</div>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Балканфарма-Разград АТ.</span><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman","serif";mso-fareast-font-family:"Times New Ro=
man";
mso-ansi-language:UK;mso-fareast-language:UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>Балканфарма-Дупниця АТ.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b><span lang=3DUK style=3D'font-size:12.0pt;font-fami=
ly:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><b><span lang=3DUK style=3D'font-size:12.0pt;font-fami=
ly:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Місцезнаходження виробника та його адреса місця провадження діяльності.=
 </span></b><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Бул. Апрельского восстанія 68, Разград 7200, Болгарія.<o:p></o:p></span=
></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none;mso-layout-grid-align:none;
text-autospace:none'><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman","serif";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>Вул. Самоковське шосе 3, Дупниця, 2600, Болгарія.<o:p></o:p></span></p>

</div>

</body>

</html>

------=_NextPart_01D65958.8AD6B7D0
Content-Location: file:///C:/680AE759/UA42710101_4899.files/preview.wmf
Content-Transfer-Encoding: base64
Content-Type: image/x-wmf
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------=_NextPart_01D65958.8AD6B7D0
Content-Location: file:///C:/680AE759/UA42710101_4899.files/themedata.thmx
Content-Transfer-Encoding: base64
Content-Type: application/vnd.ms-officetheme
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------=_NextPart_01D65958.8AD6B7D0
Content-Location: file:///C:/680AE759/UA42710101_4899.files/colorschememapping.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml

<?xml version=3D"1.0" encoding=3D"UTF-8" standalone=3D"yes"?>
<a:clrMap xmlns:a=3D"http://schemas.openxmlformats.org/drawingml/2006/main"=
 bg1=3D"lt1" tx1=3D"dk1" bg2=3D"lt2" tx2=3D"dk2" accent1=3D"accent1" accent=
2=3D"accent2" accent3=3D"accent3" accent4=3D"accent4" accent5=3D"accent5" a=
ccent6=3D"accent6" hlink=3D"hlink" folHlink=3D"folHlink"/>
------=_NextPart_01D65958.8AD6B7D0
Content-Location: file:///C:/680AE759/UA42710101_4899.files/header.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="windows-1251"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:m=3D"http://schemas.microsoft.com/office/2004/12/omml"
xmlns:st1=3D"urn:schemas-microsoft-com:office:smarttags"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dwindows-125=
1">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 14">
<meta name=3DOriginator content=3D"Microsoft Word 14">
<link id=3DMain-File rel=3DMain-File href=3D"../UA42710101_4899.htm">
<![if IE]>
<base href=3D"file:///C:\680AE759\UA42710101_4899.files\header.htm"
id=3D"webarch_temp_base_tag">
<![endif]><o:SmartTagType
 namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"metricconverter"/>
</head>

<body lang=3DRU>

<div style=3D'mso-element:footnote-separator' id=3Dfs>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><span style=3D'mso-special-character:footnote-separator'><![if !sup=
portFootnotes]>

<hr align=3Dleft size=3D1 width=3D"33%">

<![endif]></span></p>

</div>

<div style=3D'mso-element:footnote-continuation-separator' id=3Dfcs>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><span style=3D'mso-special-character:footnote-continuation-separato=
r'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1>

<![endif]></span></p>

</div>

<div style=3D'mso-element:endnote-separator' id=3Des>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><span style=3D'mso-special-character:footnote-separator'><![if !sup=
portFootnotes]>

<hr align=3Dleft size=3D1 width=3D"33%">

<![endif]></span></p>

</div>

<div style=3D'mso-element:endnote-continuation-separator' id=3Decs>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><span style=3D'mso-special-character:footnote-continuation-separato=
r'><![if !supportFootnotes]>

<hr align=3Dleft size=3D1>

<![endif]></span></p>

</div>

<div style=3D'mso-element:footer' id=3Df1>

<p class=3DMsoFooter align=3Dcenter style=3D'text-align:center'><!--[if sup=
portFields]><span
style=3D'font-size:9.0pt;mso-bidi-font-size:11.0pt;font-family:"Times New R=
oman","serif"'><span
style=3D'mso-element:field-begin'></span><span
style=3D'mso-spacerun:yes'> </span>PAGE<span style=3D'mso-spacerun:yes'>  
</span>\* MERGEFORMAT <span style=3D'mso-element:field-separator'></span></=
span><![endif]--><span
style=3D'font-size:9.0pt;mso-bidi-font-size:11.0pt;font-family:"Times New R=
oman","serif"'><span
style=3D'mso-no-proof:yes'>1</span></span><!--[if supportFields]><span
style=3D'font-size:9.0pt;mso-bidi-font-size:11.0pt;font-family:"Times New R=
oman","serif";
mso-no-proof:yes'><span style=3D'mso-element:field-end'></span></span><![en=
dif]--><span
style=3D'font-size:9.0pt;mso-bidi-font-size:11.0pt;font-family:"Times New R=
oman","serif"'><o:p></o:p></span></p>

<p class=3DMsoFooter><o:p>&nbsp;</o:p></p>

</div>

</body>

</html>

------=_NextPart_01D65958.8AD6B7D0
Content-Location: file:///C:/680AE759/UA42710101_4899.files/filelist.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml; charset="utf-8"

<xml xmlns:o=3D"urn:schemas-microsoft-com:office:office">
 <o:MainFile HRef=3D"../UA42710101_4899.htm"/>
 <o:File HRef=3D"preview.wmf"/>
 <o:File HRef=3D"themedata.thmx"/>
 <o:File HRef=3D"colorschememapping.xml"/>
 <o:File HRef=3D"header.htm"/>
 <o:File HRef=3D"filelist.xml"/>
</xml>
------=_NextPart_01D65958.8AD6B7D0--
